incorporating inh for type2
Post on 30-May-2018
229 Views
Preview:
TRANSCRIPT
-
8/9/2019 Incorporating INH for Type2
1/77
-
8/9/2019 Incorporating INH for Type2
2/77
During the presentation, various
inhaled human insulintreatments are also referred to
by brand name for purposes of
clarity only.
-
8/9/2019 Incorporating INH for Type2
3/77
Behavioral Risk Factor Surveillance System, Centers for Disease Control and Prevention. Available at:http://www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/ andhttp://www.cdc.gov/diabetes/statistics/prev/state/. Accessed January 20, 2006.
Obesity
No Data
-
8/9/2019 Incorporating INH for Type2
4/77
American Diabetes Association Diabetes Statistics. Available at:http://www.diabetes.org/diabetes-statistics.jsp. Accessed March 28, 2007.
Prevalence of Diabetes in People Aged 20
Years and Older in the US
20.8 million people (7.0% of population) have diabetes 10% of adult men; 8.8% of adult women
20.9% of people aged 60 years or older
>90% have type 2 diabetes
>6 million people are undiagnosed
1.5 million new cases of diabetes diagnosed annually
Almost 21 million Americans now have diabetes and more than 90% of thecases are type 2 diabetes. Included in this number are over 6 million peoplewho are not yet diagnosed. Almost 10% of the adult population and over20% of those 60 years of age or older have diabetes. About 1.5 million newcases of diabetes are diagnosed annually.
-
8/9/2019 Incorporating INH for Type2
5/77
-
8/9/2019 Incorporating INH for Type2
6/77
In the diabetes control and complicationstrial (DCCT), the reduction of A1C from9.1% to 7.3% was accompanied by a
retinopathy reduction of __ %?
A. 9%
B. 63%
C. 36%
D. 77%
-
8/9/2019 Incorporating INH for Type2
7/77
* A1C goal for individual patient is as close to normal (
-
8/9/2019 Incorporating INH for Type2
8/77
The ADA recommends that A1C levels are
assessed at least ___ times per year in
patients with type 2 diabetes whose A1C
levels are >7%.
A. One
B. Two
C. Three
D. Four
-
8/9/2019 Incorporating INH for Type2
9/77
American Diabetes Association. Diabetes Care. 2007;30(suppl 1):S4-S41.
Nonglycemic Goals for Diabetes
Management
Hypertension Goal 1 other cardiovascular riskfactor(s)
Cigarette smoking goal Cessation
There are also goals for the treatment of blood pressure and dyslipidemia. The goal forblood pressure is less than 130/80 mm of mercury. The LDL cholesterol goal is less than100 mg/dL with less than 70 mg/dL being an option if patients also have existingcardiovascular disease. The HDL goal in men is greater than 40 mg/dL and in womengreater than 50 mg/dL and the goal for triglycerides is less than 150 mg/dL. Low dose
aspirin should be prescribed to adult patients with diabetes and macrovascular disease orfor primary prevention in those greater than the age of 40 years or who have additional riskfactors. Aspirin can be considered in people between the age of 30 and 40 years,particularly in the presence of other cardiovascular risk factors.
-
8/9/2019 Incorporating INH for Type2
10/77
CVD is a diabetes comorbidity and the major
cause of mortality in diabetes patients. Diabetes
patients who are treated more intensively
experience less CVD comorbidity. Nathan et al
were able to demonstrate that intensive treatment
can reduce CVD risk by ___%?
A. 18%B. 42%C. 78%D. 25%
-
8/9/2019 Incorporating INH for Type2
11/77
Saaddine JB, et al. Ann Intern Med. 2006;144:465-474.
So, how well are we meeting these goals?
Saaddine: 465a,466a,b
-
8/9/2019 Incorporating INH for Type2
12/77
Saaddine JB, et al. Ann Intern Med. 2006;144:465-474.
National Health and Nutrition ExaminationSurvey (19881994 and 19992002)
and Behavioral Risk Factor SurveillanceSystem (1995 and 2002)
Survey participants 18 to 75 years of age whoreported a diagnosis of diabetes
A recent paper by Saaddine and colleagues reviewed The National Health andNutrition Examination Survey between 1988 and 1994 and again from 1999 to 2002and also looked at the Behavioral Risk Factor Surveillance System reports from1995 and 2002. Survey participants were 18 to 75 years of age who reported adiagnosis of diabetes.
Saaddine: 465a,466a,b
-
8/9/2019 Incorporating INH for Type2
13/77
LDL
-
8/9/2019 Incorporating INH for Type2
14/77
Dyslipidemias are major contributors to CVD, the major
cause of mortality in diabetes patients. ADA
recommendations for LDL, triglyceride, and HDL levels
respectively in diabetic adults are ___mg/dL, __mg/dL,and __mg/dL?
A. 50 inwomen)
B. 50 in men)
C.
-
8/9/2019 Incorporating INH for Type2
15/77
A1C of 6% to 8% increased
from 34.2% to 47.0%
A1C >9%: 24.5% 20.6% NS
A1C
-
8/9/2019 Incorporating INH for Type2
16/77
Laboratory database analysis of >157,000 patients with type 2 diabetes
in 39 states showed 67% had A1C levels exceeding goal of6.5%
AACE. State of Diabetes in America: Striving for Better Control. Available at:http://www.aace.com/public/awareness/stateofdiabetes/DiabetesAmericaReport.pdf.Page 6. Accessed March 27, 2007.
State of Diabetes in America
AACE Report for 20032004
The American Association of Clinical Endocrinologists State of Diabetes inAmerica reported on a laboratory database analysis of over a 157,000patients with type 2 diabetes in 39 states. It showed that over two-thirds hadA1C levels exceeding the goal of 6.5% or less and in every state more thanhalf of the people were above this goal.
AACE state:3a, 6a
-
8/9/2019 Incorporating INH for Type2
17/77
Why Patients Dont Achieve Goal
Lack of optimal healthcare delivery systems Suboptimal use of diabetes education
Suboptimal patient adherence to lifestyle andpharmacologic treatments
Reimbursement issues
Failure of clinicians to adopt treat-to-targetapproach
Failure to advance therapy and especially toadd insulin in a timely manner
So, why don't patients achieve goal? Well, there is a lack of optimalhealthcare delivery systems and particularly suboptimal use of diabeteseducation, a crucial resource in the management of people with diabetes.There is suboptimal patient adherence to both lifestyle and pharmacologictreatments. There are a number of reimbursement issues and there is
failure of clinicians to adopt a treat-to-target approach and particularlysometimes the failure to advance therapy, and especially to add insulin in atimely manner. These all contribute to the failure to achieve goal.
-
8/9/2019 Incorporating INH for Type2
18/77
For patients using multiple daily insulin
injections, self-monitoring of blood
glucose should be conducted___ ?
A. Once daily
B. Twice daily
C. Every 12 hours
D. At least 3 times a day
-
8/9/2019 Incorporating INH for Type2
19/77
www.BetterDiabetesCare.nih.gov
From the NDEP
The National Diabetes Education Program has created a website,www.betterdiabetescare.nih.gov, to help clinicians better organize the care theydeliver to patients with diabetes using principles of the Chronic Care Model.
-
8/9/2019 Incorporating INH for Type2
20/772
Why Patients Dont Achieve Goal
Lack of optimal healthcare delivery systems
Suboptimal use of diabetes education
Suboptimal patient adherence to lifestyle andpharmacologic treatments
Reimbursement issues
Failure of clinicians to adopt treat-to-target approach
Failure to advance therapy and especially to addinsulin in a timely manner
So, lets focus on the fact that clinicians don't always adopt a treat-to-targetapproach and there is often a failure to advance therapy and especially toadd insulin in a timely manner.
-
8/9/2019 Incorporating INH for Type2
21/772
Therapy Is Not Modified* Soon Enough
8.2
7.7
8.8
7.6
7.1
9.1
5
6
7
8
9
10
Metforminmonotherapy
Sulfonylurea
monotherapy
A1C%
First A1C on
Treatment
Last A1C Before
Switch or Addition
35 Months**
27 Months**
ADA goal
AACE goal
Best A1C on
Treatment
0
*Monotherapy switched to another agent or additional agent added. **Meannumber of months that elapsed until a new or additional treatment was started.
Brown JB, et al. Diabetes Care. 2004;27:1535-1540.
Brown and colleagues conducted a prospective population-based study analyzingobservational data on over 7000 complete courses of diabetes treatment. Amongpeople on monotherapy with metformin or a sulfonylurea the first A1C on treatmentwas significantly above goal. Even the best A1C on monotherapy was above goal.The last A1C before a switch or addition of medication was 8.8% or greater and the
time from the best A1C to the last A1C average 27 to 35 months. The averagepatient accumulated nearly 5 years with an A1C above 8% from diagnosis untilstarting insulin and about 10 years with an A1C above 7% before starting insulin.
Brown: 1537a,b
-
8/9/2019 Incorporating INH for Type2
22/772
In spite of the fact that type 2 diabetes is a
progressive disease in which patients drug
regimens are likely to become more
complicated over time, the percentage of OADtreated patients is going up but the percentage
of insulin treated patients remains the same.
A. True
B. False
-
8/9/2019 Incorporating INH for Type2
23/772
Insulin Use in the US Remains UnchangedDespite Poor Control
Between NHANES III (1988-1994) and NHANES (1999-2000), the percentage of OA-
treated patients increased ~7%. NHANES, National Health and Nutrition ExaminationSurvey.
Adapted from: Koro CE, et al. Diabetes Care2004;27:17-20.
NHANES III (1988-1994) versus NHANES (1999-2000)
NHANES III (1988-1994) NHANES (1999-2000)
0
10
20
30
40
50
60
Patients(%)
Diet Only
27.4
20.2
OAs
45.452.5
OAs +
Insulin
3.1
11.0
Insulin Only
24.2
16.4
Constant: 27% of patients
treated with insulin
An analysis of NHANES III and NHANES 1999 through 2000 showed thatdespite the fact that most people failed to achieve goal glycemia, only 27% ofpatients were treated with insulin and that number had not increased during thetime interval between the 2 studies.
-
8/9/2019 Incorporating INH for Type2
24/772
Fear ofInjection
Permanenceof Having toTake Insulin
PersonalFailure inManagingDiabetes
Fear of theDemands of
Insulin Therapy
Inconvenienceof Monitoring
56.1%53.1%58.1%
55.0%50.8%
100
80
60
40
20
0
Patients(%)
Polonsky WH, et al. Diabetes Care. 2005;28:2543-2545.
Unwilling Patients: Barriers to
the Use of Insulin
Polonsky and colleagues asked people with diabetes to complete a questionnairedesigned to assess their attitudes toward taking insulin. Of the more than 1200diabetic patients who returned the questionnaire, 708 were people with Type 2diabetes who were not taking insulin. On the first question, which asked people torate their willingness to begin insulin therapy, almost 30% reported that they would
be unwilling to take insulin if it was prescribed. In the remaining questions, thosepeople who said that they were unwilling to take insulin identified fear of injectionand fear of the demands of insulin therapy, as well as concern that once startinginsulin it would have to be taken indefinitely forever--or that insulin therapy wouldmean that they had failed to do a good job, or that insulin monitoring would be tooinconvenient and restrictive as barriers to initiation of insulin.
-
8/9/2019 Incorporating INH for Type2
25/772
American Association of Clinical Endocrinologists (AACE)/American College ofEndocrinology (ACE) Road Maps:
www.aace.com
www.aace.com/meetings/consensus/odimplementation/roadmap.pdf
American Diabetes Association (ADA) Standards of Care and ConsensusAlgorithm for the Initiation and Adjustment of Antihyperglycemic Therapy
http://care.diabetesjournals.org/cgi/content/full/30/suppl_1/S4
Diabetes Care. 2006;29:1963-1972.
Texas Diabetes CouncilInsulin Algorithm for T2DM
www.dshs.state.tx.us/diabetes/PDF/algorithms/PHARM2.PDF
National Diabetes Education Program:
www.ndep.nih.gov
www.BetterDiabetesCare.nih.gov
Resources to Help Clinicians Achieve
Glycemic Targets
Free, non-copyrighted, reproducible patient education materials and resources tohelp healthcare professionals better understand and treat diabetes, including acomprehensive Medication Supplement.
On this slide I have aggregated a number of web resources that should be able tohelp clinicians better achieve glycemic targets. Included are the AmericanAssociation of Clinical Endocrinologist Road Maps, the new American DiabetesAssociation, European Association for the Study of Diabetes Consensus Algorithmfor Antihyperglycemic Therapy, an algorithm from the Texas Diabetes Council and
websites of the National Diabetes Education Program, a partnership of the NationalInstitutes of Health, the Centers for Disease Control and Prevention and more than200 public and private organizations working to change the way diabetes is treated.
-
8/9/2019 Incorporating INH for Type2
26/772
AACE Road Maps (www.aace.com)
ACE/AACE Diabetes Roadmap Task Force. Roadmap for the Prevention and Treatmentof Type 2 Diabetes. Available at:http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf. AccessedMarch 28, 2007.
The AACE Road Maps are a comprehensive guide to therapy for people with or atrisk for diabetes.
-
8/9/2019 Incorporating INH for Type2
27/772
Nathan DM, et al. Diabetes Care. 2006;29:1963-1972.
The American Diabetes Association and the European Association for the Study ofDiabetes recently published a paper entitled Management of Hyperglycemia inType 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment ofTherapy.
-
8/9/2019 Incorporating INH for Type2
28/772
Anti-hyperglycemic Agentsin Type 2 Diabetes
ClassA1C
Reduction, % HypoglycemIaWeightchange
Dosing,
times/day
Insulin 1.5 to 2.5 Yes Gain1 to 4
injected
Sulfonylureas 1.5 Yes Gain 1
Glinides 1 to 1.5 Yes Gain 3
Biguanides (metformin) 1.5 No Neutral 2
Thiazolidinediones,glitazones
0.5 to 1.4 No Gain 1
Alpha-glucosidase inhibitors 0.5 to 0.8 No Neutral 3
Amylin-mimetics(pramlintide)
0.5 to 1.0 No Loss3
injected
Incretin agonists (exenatide) 0.5 to 1.0 No Loss2
injected
DPP-4 inhibitors 0.6 to 0.8 No Neutral 1
Adapted from Nathan DM, et al. Diabetes Care. 2006;29:1963-1972.
Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2006.
The document reviewed the efficacy and safety of antihyperglycemic agents for thetreatment of type 2 diabetes. Some of the comments about these therapies areshown on this slide.
-
8/9/2019 Incorporating INH for Type2
29/772
A 45-year-old male type 2 diabetes patient taking
2 oral antidiabetic agents (OADs) for 2 years is in
for a check-up and has A1C of 8.5%, fastingpreprandial and 2-hour postprandial glucose of
180 and 220 mg/dL, respectively. Which
therapeutic initiative is preferred by the
American Diabetes Association (ADA/ EASD
consensus algorithm statement)?
A. Add third OAD
B. Initiate insulin therapy
C. Intensify diet and exercise interventionD. Switch OAD
-
8/9/2019 Incorporating INH for Type2
30/773
Management of Hyperglycemia in Type 2 Diabetes
Diagnosis
Lifestyle Intervention + Metformin
A1C 7%No Yes*
Add Basal Insulin Most effective
Add Sulfonylurea Most effective
Add Glitazone No hypoglycemia
Intensify Insulin# Add Glitazone+ Add Basal Insulin# Add Sulfonylurea
Add Basal or Intensify Insulin#
Intensive Insulin+ Metformin +/- Glitazone
A1C 7%No Yes*A1C 7%No Yes
A1C 7%No Yes
A1C 7%No Yes*
A1C 7%No Yes
*Check A1C every 3 months until
-
8/9/2019 Incorporating INH for Type2
31/773
Insulin in Management of
Hyperglycemia in Type 2 Diabetes
Nathan DM, et al. Diabetes Care2006;29:1963-1972.
Insulin is the most effective of the availablediabetes medications for lowering glycemia
It can, when used in adequate doses, decreaseany level of elevated A1C to, or close to, thetherapeutic goal
Unlike the other blood glucose-loweringmedications, there is no maximum dose ofinsulin beyond which a therapeutic effect willnot occur
The importance of insulin is emphasized by the consensus statement, which notedthat insulin is the most effective of the available diabetes medications for loweringglycemia. It can, when used in adequate doses, decrease any level of elevatedA1C to or close to the therapeutic goal. Unlike the other blood glucose loweringmedications, there is no maximum dose of insulin beyond which a therapeutic effect
will not occur.
-
8/9/2019 Incorporating INH for Type2
32/773
Triple Therapy in Type 2 Patients
Adapted from: Rosenstock J, et al. Diabetes Care. 2006;29:554-559.
A1C(%)
Time
(weeks)
9
8.5
8
7.5
7
6.5
4 8 12 16 20 24
Insulin glargine
Rosiglitazone
Mean A1C Levels From
Baseline to End Point
70
Changefromb
aseline
InA1C(%)
-0.5
-1.0
-1.5
-2.0
-2.5
-3.0
-3.5
7.5 8 8.5 9 9.5 10 10.5 11
Insulin glargine
Rosiglitazone
Glycemic Control by Baseline A1C
Time (weeks)
When people with diabetes do not achieve goal despite a combination of 2 oralagents, one can initiate additional agents. In this study patients not at goal despitetreatment with metformin and a sulfonylurea were randomized to receive theaddition of either the thiazolidinedione rosiglitazone or insulin glargine, a basalinsulin. Similar glycemic control was achieved with both regimens. But when the
results were stratified by baseline A1C, insulin glargine showed better efficacy inthose individuals whose A1C at baseline was 9.5% or higher.
-
8/9/2019 Incorporating INH for Type2
33/773
Initiation of Insulin in Patients With
Type 2 Diabetes
Nathan DM, et al. Diabetes Care. 2006;29:1963-1972.
If lifestyle, metformin, and a second medication do not resultin goal glycemia, the next step should be to start, or intensify,insulin therapy.
When A1C is close to goal (8.0%), addition of a third oralagent could be considered;
However, this approach is relatively more costly andpotentially not as effective in lowering glycemia comparedwith adding or intensifying insulin.
The consensus statement noted that if lifestyle, metformin, and a secondmedication did not result in goal glycemia, the next step should be to start orintensify insulin therapy. When A1C is close to goal, around 8% or less, addition ofa third oral agent could be considered. However, in the opinion of the consensusstatement, this approach is relatively more costly and potentially not as effective in
lowering glycemia compared with adding or intensifying insulin.
-
8/9/2019 Incorporating INH for Type2
34/773
Eventually Most Type 2 Diabetes
Patients Are Likely to Require Insulin
Therapy
Eventually, most type 2 diabetes patients are likely to require insulin therapy.
-
8/9/2019 Incorporating INH for Type2
35/773
Insulin Administration Should Attempt
to Emulate Endogenous Insulin Profiles
Seen in Non-diabetic Individuals
When using insulin one should attempt to emulate endogenous insulin profiles seenin non-diabetic individuals.
-
8/9/2019 Incorporating INH for Type2
36/773
Basal/Bolus Insulin Absorption Pattern
With Standard Insulin Preparations
Adapted from: Skyler J. In: Humes HD, Dupont HL, eds. Kelleys Textbook ofInternal Medicine. 4th ed. Philadelphia, Pa: Lippincott; 2000.
PlasmaInsulin(U/mL)
Time
4:00 8:00 12:00 16:00 20:00 24:00 4:00 8:00
NPH
LunchBreakfast Dinner 75
50
25
0
Slide 3-22
When a non-diabetic individual eats a meal, they get a burst of insulin thatcontrols their postprandial or post-meal glucose. Between meals andovernight there is a low but steady level of basal insulin that maintainsglucose values in the normal range. NPH insulins are not ideal basalinsulins. They tend not to last 24 hours and their glycemic profiles exhibit
peaks rather than maintaining a uniform or flat level of insulin throughouttheir activity period. Failure to last 24 hours can result in periods ofhyperglycemia, while the peak insulin levels can be associated with anincreased risk for hypoglycemia.
-
8/9/2019 Incorporating INH for Type2
37/773
Basal/Bolus Insulin Absorption Pattern
With Standard Insulin Preparations
Adapted from: Skyler J. In: Humes HD, Dupont HL, eds. Kelleys Textbook of InternalMedicine. 4th ed. Philadelphia, Pa: Lippincott; 2000.
Time
PlasmaInsulin(U/mL)
4:00 8:00 12:00 16:00 20:00 24:00 4:00 8:00
75
NPH
LunchBreakfast Dinner
50
25
0
GLARGINE/DETEMIR
Slide 3-22
Insulin glargine and insulin detemir are better basal insulins and better mimicbasal insulin secretion that occurs in non-diabetic individuals. These arebasal insulin analogues that tend to last up to 24 hours and they have aflatter insulin profile that is more uniform.
-
8/9/2019 Incorporating INH for Type2
38/773
Basal/Bolus Insulin Absorption Pattern
With Standard Insulin Preparations
Adapted from: Skyler J. In: Humes HD, Dupont HL, eds. Kelleys Textbook of InternalMedicine. 4th ed. Philadelphia, Pa: Lippincott; 2000.
Time
PlasmaInsulin(U/mL)
4:00 8:00 12:00 16:00 20:00 24:00 4:00 8:00
75
NPH
LunchBreakfast Dinner
50
25
0
GLARGINE/DETEMIR
Slide 3-22
Similarly, regular human insulin peaks too late and lasts too long to be anoptimum mealtime insulin.
-
8/9/2019 Incorporating INH for Type2
39/773
Basal/Bolus Insulin Absorption Pattern
With Standard Insulin Preparations
Adapted from: Skyler J. In: Humes HD, Dupont HL, eds. Kelleys Textbook of InternalMedicine. 4th ed. Philadelphia, Pa: Lippincott; 2000.
PlasmaInsulin(U/mL)
Time4:00 8:00 12:00 16:00 20:00 24:00 4:00 8:00
NPH
GLARGINE
INH INH
LunchBreakfast Dinner
Lispro/Aspart/
Glulisine
Lispro/Aspart/
Glulisine
75
50
25
0
INHLispro/Aspart/
Glulisine
Slide 3-22
Injectable rapid-acting insulin analogs, insulin lispro, insulin aspart, andinsulin glulisine have a much more rapid onset and offset of action and bettermimic endogenous mealtime insulin secretion that occurs in non-diabeticindividuals. Similarly, inhaled insulin has a more rapid onset of action than(subcutaneously) injected regular human insulin.
-
8/9/2019 Incorporating INH for Type2
40/774
Basal Insulin Therapy
Controls glycemia between mealsand overnight
QD or BID administration
Options:
Long-acting insulin analogs(glargine, detemir)
Human insulin (NPH)
Cefalu WT, et al, eds. The CADRE Handbook of Diabetes Management. 1stEdition. New York, NY: Medical Information Press; 2004.
Basal insulin therapy controls glycemia between meals and overnight. Itusually involves daily or twice daily administration. One can use the long-acting insulin analogs, insulin glargine, and insulin detemir. One could alsouse human NPH insulin.
-
8/9/2019 Incorporating INH for Type2
41/774
8.5
9.0
8.0
7.5
7.0
6.5
0 4 8 12 16 20 24
A1C(%)
NPH + OAD
Glargine + OAD
Weeks
Once-daily Glargine vs NPH inTreat-to-Target Trial: A1C and Hypoglycemia
NPH neutral proamine hagadorn; OAD oral anti-diabetic (therapy)
Adapted from: Riddle MC, et al. Diabetes Care. 2003;26:3080-3086.
0
2
4
6
8
10 44% risk
reduction
P
-
8/9/2019 Incorporating INH for Type2
42/774
Twice-daily Detemir vs NPH inTreat-to-Target Trial: A1C and Hypoglycemia
Adapted from: Hermansen K, et al. EASD 2004. Poster 754:PS 64.
55% risk
reduction
P
-
8/9/2019 Incorporating INH for Type2
43/774
Post-prandial Glucose Contribution to A1C
A1C Range (%)
Fasting plasma
glucose (FPG)
Post-prandial
glucose (PPG)
Adapted from: Monnier L, et al. Diabetes Care2003;26:881-885.
30
70
>10.2
Contribution(%)
0
20
40
60
80
100
9.3-
10.2
8.5-9.2
70
30
60
40
55
45
7.3-
8.4
50
50
-
8/9/2019 Incorporating INH for Type2
44/774
Pre-mixed Insulin Therapy
Contains both prandial and longer acting insulin Usually administered 2 or more times per day
Options:
70/30 NPH/regular insulin
70/30 protamine aspart (NPA)/aspart insulin
75/25 protamine lispro (NPL)/lispro
50/50 protamine lispro (NPL)/lispro
Cefalu WT, et al, eds. The CADRE Handbook of Diabetes Management. 1stEdition. New York, NY: Medical Information Press; 2004; Hirsch IB. Medscape GenMed. 2005;7:49. Available at: http://www.medscape.com/viewarticle/515847.Accessed March 28, 2007.
Premixed insulin therapies contain both prandial and longer-acting insulin,they are usually administered 2 or more times per day. The various optionsare shown on this slide.
-
8/9/2019 Incorporating INH for Type2
45/774
Goal Achievement With Biphasic Insulin
Aspart 70/30: The 1-2-3 Study
ITT Population (N = 100)
Adapted from: Garber AJ, et al. Diabetes Obes Metab. 2006;8:58-66.
A1C 6.5% A1C
-
8/9/2019 Incorporating INH for Type2
46/774
Premixed Insulin
May be simpler approach to initiating insulin in patients withpoorly controlled (PG >8.5%)
Difficult to achieve A1C
-
8/9/2019 Incorporating INH for Type2
47/774
Prandial, Bolus, or Pre-meal Insulin
Addresses hyperglycemia after meals Administered 1 to 3x/day
Options
Short-acting (regular) injectable insulin
Rapid-acting (aspart, lispro, glulisine) injectableinsulin analogs
Inhaled insulin
Cefalu WT, et al, eds. The CADRE Handbook of Diabetes Management. 1st Edition.New York, NY: Medical Information Press; 2004.
One can address postprandial hyperglycemia more specifically by using aprandial bolus or premeal insulin. These are administered 1 to 3 times a daybefore meals, the options are short-acting regular human injectable insulin,rapid-acting insulin aspart, insulin Lispro, insulin glulisine, which areinjectable insulin analogs, or inhaled insulin.
-
8/9/2019 Incorporating INH for Type2
48/774
Insulin Time-Action Profile
0
20
40
60
80
100
0 60 120 180 240 300 360 420 480 540 600
MaximalGluc
ose
InfusionRate
(%)
Time (min)
Lispro
Regular
Inhaled
Adapted from: Rave K, et al. Diabetes Care. 2005;28:1077-1082.
This slide shows glucose infusion rates as a measure of the time course ofinsulin action in healthy volunteers. Rapid-acting insulin analog lispro has amore rapid onset of glucose lowering activity than subcutaneously injectedregular human insulin. Exubera, the first FDA-approved inhaled insulin hasan onset of glucose-lowering activity within 10 to 20 minutes, and maximum
effect in about 2 hours similar to what is seen with injected insulin lispro.The duration of glucose lowering activity with Exubera is comparable to thatof subcutaneously injected human insulin.
-
8/9/2019 Incorporating INH for Type2
49/774
0
2
4
6
8
10
12
0 1 2 3 4 5 6 7 8 9 10
Pfizer/Aventis/Nektar
Time (h)
Glucose infusion rates (mg/kg/min)
Aerogen
Lilly/AIR/Alkermes
MannKind
Technosphere
Novo Nordisk/Aradigm
15 U Lispro s.c.
Data from different studies
KOS
GIR
Adapted from: Heinemann L, et al. Br J Diab Vasc Dis.2004;4:295-301.
Time-Action Profile of Inhaled Insulin
This slide shows the insulin time action profiles of lispro and Exubera, as wellas several other inhaled insulin products that are presently underdevelopment but not yet FDA approved. All but 1 have similar time actionprofiles to that of Exubera. The MannKind Technosphere insulin producthas a more rapid onset and offset of action than the others.
-
8/9/2019 Incorporating INH for Type2
50/775
Adding Prandial Insulin to Basal Insulin
Nathan DM, et al. Diabetes Care. 2006;29:1963-1972.
If A1C above goal when FBG in target range (70-130 mg/dL),
check BG pre-lunch, dinner, and bed; depending on BGresults, add second injection with rapid acting insulin; can
usually begin with ~4 units and adjust by 2 units/3 days until BGin range
Pre-lunch BG aboverange add RAI at
breakfast
Pre-dinner BGabove range add
RAI at lunch
Pre-bedtime BGabove range add
RAI at dinner
BG - blood glucose; FBG fasting blood glucose; RAI rapid-acting insulin
The ADA-EASD algorithm recommends that if the A1C remains above goal, oncethe fasting glucose is in the target range, that one should perform SMBG beforelunch, dinner, and bedtime; and depending on these results add a second injectionusing rapid-acting insulin. One can usually begin with about 4 units and adjust by 2units every 3 days until the blood glucose is in range. So if the pre-lunch SMBG is
above range, one can add rapid-acting insulin at breakfast. If the pre-dinner SMBGis above range, one should add rapid-acting insulin at lunch. And if the pre-bedtimeSMBG is above range, one can add rapid-acting insulin at dinner. One could alsouse inhaled insulin in these circumstances as a prandial insulin now that it isavailable.
-
8/9/2019 Incorporating INH for Type2
51/775
Basal Bolus Insulin Regimen
Basal insulin administered QHS, QAM or BID Preferably using long acting insulin analog
Prandial insulin administered before meals
Preferably using rapid acting insulin analog orinhaled insulin
Basal insulin adjusted to control FPG
Prandial insulin adjusted to control PPG
With the addition of pre-meal insulin, we evolve to a basal bolus insulin regimenwhere the basal insulin is administered at bedtime, in the morning or twice a daypreferably using a long-acting insulin analog. The prandial insulin is administeredbefore meals preferably using rapid-acting insulin analog or inhaled insulin. Thebasal insulin is adjusted to control the fasting plasma glucose. The prandial insulin
is adjusted to control the post prandial glucose.
-
8/9/2019 Incorporating INH for Type2
52/775
Barriers to Basal/Bolus Insulin Therapy
Patients and physicians may have little experience with it andbelieve it is too complex
Requires diabetes self-management education support whichmay not be readily available
Requires multiple daily administrations of insulin
Requires performance of SMBG multiple times/day
The barriers to initiation of basal bolus insulin therapy include the fact that patientsand physicians may have little experience with it and believe its too complex, itrequires diabetes self management education support which may not always bereadily available, it requires multiple daily administrations of insulin and requiresperformance of SMBG multiple times per day.
-
8/9/2019 Incorporating INH for Type2
53/775
Benefits of Basal/Bolus Insulin Therapy
Improved glycemic control Greater flexibility in timing and quantity of meals
and activity
Reduced risk for hypoglycemia
Less likelihood of weight gain
Patient can be empowered to take control ofinsulin therapy adjustments
So, the benefits of basal bolus insulin therapy can be improved glycemic control,greater flexibility in timing and quantity of meals and activity, a reduced risk forhypoglycemia, less likelihood of excessive weight gain and the patient can be taughtand be empowered to take control of their insulin therapy adjustments.
-
8/9/2019 Incorporating INH for Type2
54/775
Prandial insulin therapy is usually
initiated after basal insulin treatment
However, prandial insulin can be used to
first initiate insulin therapy
Prandial insulin therapy is usually initiated after basal insulin treatment.However, prandial insulin can be used to first initiate insulin therapy.
-
8/9/2019 Incorporating INH for Type2
55/775
Targeting Postprandial Glucose
Lowers A1C
11
10
9
8
7
A1C
(%)
P= 0.003
P = 0 .025 P = 0 .445
11
10
9
87
6
Fasting
Blo
odGlucose
(mmol/L)
P< 0.001
P= 0.108 P= 0.029
2-hourPostprandial
GlucoseExcursion
(mmol/L)
P< 0.001
P< 0.001 P= 0.1334
3
2
1
0 L+G M+G NPH+G
Treatment Groups
14
13
12
11
10
9
8
P= 0.052
P= 0.009 P= 0.454
2-hour
PostprandialGlucose
(mmol/L)
L+G M+G NPH+G
Treatment Groups
Adapted from: Bastyr EJ, et al. Diabetes Care. 2000;23:1236-1241.
A
DC
B
M + G = Metformin + GlyburideNPH + G = NPH Insulin + Glyburide
L + G = Lispro + Glyburide
In this study by Bastyr and colleagues, 135 type 2 diabetes patients notadequately controlled with oral sulfonylurea agents alone were randomlyassigned for 3 months to 1 of 3 combination regimens with glyburide. Theseregimens were the addition of NPH insulin to glyburide at bedtime, the addition ofmetformin to glyburide or the addition of insulin lispro before meals with glyburide.One can see that the best control of fasting blood glucose occurred with theregimen that combined NPH insulin and glyburide. However the combination ofpremeal or prandial insulin lispro with glyburide resulted in the best control of two-
hour post prandial glucose. The best control of 2-hour postprandial glucoseexcursion and the best control of A1C, so the addition of a prandial insulin can bean effective way to initiate insulin therapy but many patients might be reluctant togo from no injections of insulin a day to 3 injections a day.
-
8/9/2019 Incorporating INH for Type2
56/775
Mealtime Inhaled Human Insulin* Substituted for
or Added to Combination Oral Agents309 Patients on Combination Oral Agents With A1C 8%
* Exubera; Pfizer Inc. [New York, New York], sanofi-aventis Groupe [Paris, France], and NektarTherapeutics [San Carlos, California]). INH = inhaled insulin; OA = secretagogue + metformin orthiazolidinediones; P
-
8/9/2019 Incorporating INH for Type2
57/775
Inhaled Insulin
Newest approved form of insulin
Prandial rapid onset insulin
Delivered by pulmonary inhalation
Inhaled insulin, or Exubera, is the newest approved form of insulin. It is a prandialrapid onset insulin that is delivered by pulmonary inhalation.
-
8/9/2019 Incorporating INH for Type2
58/775
Pulmonary Insulin Delivery System
(Pfizer/Nektar)
Exubera is a product of an alliance between Pfizer and Nektar Therapeutics and thepulmonary insulin delivery system consists of dry powder human insulin particlesthat are packaged in blisters that are then inserted in to the delivery device.Mechanical pressure turns this into a cloud of insulin particles that are then inhaledinto the deep lung and rapidly absorbed into the bloodstream.
-
8/9/2019 Incorporating INH for Type2
59/775
Other Inhaled Insulins in Development
Alkermes AIR
Particle Technology BreathActuated Pulmonary Insulin Delivery System(Lilly)
Aradigm AERx iDMS Pulmonary InsulinDelivery System (Novo-Nordisk)
TechnosphereTM Pulmonary Insulin DeliverySystem (Mannkind)
Breath Actuated Inhaler Pulmonary InsulinDelivery System (Kos)
Other inhaled insulins are presently in development. These include theLilly/Alkermes Air Particle Technology System, the Novo-Nordisk/Aradigm AERxiDMS System, The MannKind Technosphere Pulmonary Insulin Delivery System,and the KOS Breath Actuated Inhaler Pulmonary Insulin Delivery System.
-
8/9/2019 Incorporating INH for Type2
60/776
Effectiveness of Pulmonary
Delivery of Insulin
What is the effectiveness of pulmonary delivery of insulin?
-
8/9/2019 Incorporating INH for Type2
61/776
Screening Baseline 6 12 24
SC insulin (n=145)Inhaled insulin (n=143)
5
6
7
8
9
10
Duration of Treatment (weeks)
MeanA1C(%)
Type 2 Diabetes: Inhaled Insulin andConventional Insulin Therapy
Change in A1C
Adapted from: Hollander PA, et al. Diabetes Care. 2004;27:2356-2362.
In this study, type 2 diabetes patients who had previously been treated withsubcutaneously injected insulin were randomized to 6 months treatment witheither premeal inhaled insulin plus a bedtime dose of ultralente insulin or atleast 2 daily subcutaneous injections of mixed regular and NPH insulin. Youcan see that the glycemic control achieved with the 2 insulin regimens were
similar, and the goal of this study was to show that inhaled insulin wouldwork as well as conventional insulin therapy.
-
8/9/2019 Incorporating INH for Type2
62/776
0
10
20
30
40
50
Patients(%)
-
8/9/2019 Incorporating INH for Type2
63/776
Change in FPG With Inhaled Insulin
Adapted from: Hollander PA, et al. Diabetes Care. 2004;27:2356-2362
-10
0
Inhaled Insulin (Exubera)(n = 146)
SC regular insulin(n = 149)
-20
-30
-40
-60
-50
P=0.003
-22
-6
AdjustedMeanChange
FromB
aselineFPG(mg/dL)
In this study, the reduction in fasting plasma glucose was greater with the Exuberaregimen than with the regimen that used subcutaneous regular insulin before meals.In this trial some of this difference might be attributed to the fact that the basalinsulin was different between the 2 regimens but in other trials involving Exuberawhere the basal insulin was the same in the 2 comparator groups, there was still
better reduction of the fasting plasma glucose in the Exubera treated patients and agreater reduction in fasting plasma glucose then one might anticipate with a mealtime insulin that is given for the last time with the evening meal prior to the nextdays fasting plasma glucose.
-
8/9/2019 Incorporating INH for Type2
64/776
12 Week Trial of AERx vs SC Insulin
in Type 2 Diabetes Subjects
Adapted from: Hermansen K, et al. Diabetes Care. 2004;27:162-167.
9.0
8.5
8.0
7.5
7.0
0AERx SC AERx SC
Week 0 Week 12
Mean A1C before and after 12 weeks of treatment (intention-to-treat population).There was no difference in the change in A1C between the groups (P=0.60)
In this study, type 2 diabetes patients were randomized to receive either inhaled fastacting human insulin using the AERx iDMS System immediately before meals orsubcutaneously injected fast acting human insulin given 30 minutes before mealsboth in combination with evening NPH insulin. One can see that glycemic controlachieved with the 2 insulin regimens were similar, and in fact the goal of the inhaled
insulin trials has been to show that inhaled insulin would work as well assubcutaneously injected insulin.
-
8/9/2019 Incorporating INH for Type2
65/776
Technosphere Inhaled Insulin in Type 2 Diabetes
Adapted from: Rosenstock J. et al. ADA 66th Scientific Sessions.June, 2006 Washington, DC: Abstract 357 OR.
-0.76
P=0.0019 vs
placebo
-0.32Mean A1C
Change
7.74%7.75%A1C at
Baseline
Technosphere
Insulin
Technosphere
Placebo
-
8/9/2019 Incorporating INH for Type2
66/776
Inhaled Insulin in Type 2 Diabetes Not
Controlled With Diet and ExerciseAbsolute Change in A1C
6
7
8
9
10
11
Screening Baseline 6 12 Week 12
(LOCF)
MeanA1C(%)
Duration of Treatment (weeks)
Inhaled insulin (n=76)Rosiglitazone (n=69)
Adapted from: DeFronzo RA, et al. Diabetes Care. 2005;28:1922-1928.
Adjusted
mean
difference:
0.89%
What about using inhaled insulin as initial pharmacologic therapy in peoplewith type 2 diabetes who are not controlled with lifestyle measures, diet, andexercise? This study compared initiation of inhaled insulin with the use ofrosiglitazone in such patients. Twelve weeks is probably not long enough tosee the optimal effect of rosiglitazone; nevertheless, one sees a very robust
improvement in glycemic control in patients treated with inhaled insulin orExubera.
-
8/9/2019 Incorporating INH for Type2
67/776
Inhaled Insulin in Type 2 Diabetes Not
Controlled With Diet and ExerciseTreatment to Goal A1C (%)
Patients(%)
Adapted from: DeFronzo RA, et al.Diabetes Care. 2005;28:1922-1928.
Inhaled insulin
Rosiglitazone
0
10
20
30
40
50
60
7080
90P=0.0003
-
8/9/2019 Incorporating INH for Type2
68/776
Safety of Pulmonary Delivery of Insulin
What do we know about safety of pulmonary delivery of insulin?
-
8/9/2019 Incorporating INH for Type2
69/776
Incidence of Hypoglycemia With Inhaled InsulinType 1 and Type 2 Diabetes
0.050.7INH vs rosiglitazone
1.70.11.3INH or INH + OA vs OA
1.61.4
Type 2 diabetes
INH vs SC insulin
9.08.6
Type 1 diabetes
INH vs SC insulin
Inhaled Insulin+ Comparator(events/sub-
ject/month)
Comparator(events/sub-ject/month)
Inhaled Insulin(events/sub-
ject/month)
DeFronzo RA, et al. Diabetes Care. 2005;28:1922-1928; Hollander PA, et al.Diabetes Care. 2004;27:2356-2362; Quattrin T, et al. Diabetes Care. 2004;27:2622-2627; Rosenstock J, et al. Ann Intern Med. 2005;143:549-558.
As with all insulins, there is some risk for hypoglycemia with inhaled insulin.On this slide, one sees that the incidence of hypoglycemia in both type 1 andtype 2 diabetes patients is similar when one compares inhaled insulin to theuse of subcutaneously injected insulin. There is some increase in riskcompared to treatment with oral antidiabetic agents but there is also in these
trials better glycemic control with inhaled insulin than patients treated withthe oral regimens.
-
8/9/2019 Incorporating INH for Type2
70/777
Adapted from: Fineberg SE, et al. J Clin Endocrinol Metab. 2005;90:3287-3294.
Insulin Antibody Binding Responses After InhaledInsulin vs Comparator (SC Insulin or Oral Agents)
in the Initial Studies
20
40
60
0
InsulinAntibodies(median%
binding)
n=362 n=370 n=363 n=355 n=146 n=145 n=137 n=137 n=302 n=195 n=302 n=189
Noninsulinusing Type 2Patients
Insulin-using Type 2Patients
Type 1 Patients
Inhaled insulin SC insulin
Baseline
End ofStudy
+ +
+
+ + ++
+ + + + +
Baseline
End ofStudy Baseline
End ofStudy
+ = mean % bindingThe top and bottom bars represent the 75th and 25th percentile, respectively.
Insulin antibodies may develop during treatment with all insulin preparations including insubcutaneous regular insulin increases in insulin antibody levels were significantly greaType 2 diabetes. No clinical consequences of these antibodies were identified over thedeclined when Exubera was discontinued.
-
8/9/2019 Incorporating INH for Type2
71/777
Resolution of Treatment Group Differences
in FEV1 in Type 2 Diabetes (104-week
Cohort)Difference in Slopes (L/y)
Exubera vs Comparator 6-24
Months
0.000 (95% Cl: -0.032, 0.033)
Adapted from: Dreyer M. Diabetologia. 2004;47(suppl 1):A44.
Weeks
Comparative Phase Washout Phase
Exubera Oral AgentChangeFromB
aselinein
FEV
1(L)(meanSD)
-0.2
0
-0.4
0.2
24 36 52 65 78 91 104 +6 +12
Difference: -0.039 (95% Cl: -0.093, 0.015)
N=304
This slide looks at the change from baseline in FEV1
for patients treated either withExubera or oral agents over a 2-year period of time. In clinical studies, patientstreated with Exubera experienced greater declines in FEV1 and DLCO thancomparator-treated patients. The changes occurred early--within the first severalweeks of therapy. But as shown on this slide, for the remainder of the 2-year period
of time, there was no progressive difference. You see that the slope between theExubera-treated patients and the comparator-treated patients is the same after thefirst 24 weeks. The changes were small in magnitude--about 40 mLs at 2 years andmean FEV
1compared to a baseline that was approximately 3 liters. These changes
reversed 6 weeks after discontinuation of therapy in patients with type 2 diabetes.These changes were not driven by outliers, and the change from baseline in bothFEV
1and DL
COdid not correlate with the total daily dose or cumulative dose of
Exubera.
-
8/9/2019 Incorporating INH for Type2
72/777
Inhaled Insulin Safety Profile: Cough
Cough questionnaire Cough tended to occur within seconds tominutes after administering inhaled insulin
Cough was predominately mild
Cough was rarely productive and rarelyoccurred at night
Incidence of cough decreased withcontinued inhaled insulin use
In controlled clinical studies, 1.2% ofpatients discontinued inhaled insulintreatment because of cough
EXUBERA [US package insert]. New York, NY: Pfizer Labs; 2006.
Patients treated with Exubera more frequently exhibited cough than those treatedwith comparator. The cough tended to occur within seconds to minutes. AfterExubera inhalation it was predominantly mild, was rarely productive and rarelyoccurred at night. The incidence of cough decreased with continued Exubera useand 1.2% of patients discontinued Exubera treatment because of cough.
-
8/9/2019 Incorporating INH for Type2
73/777
T1DM Treatment Group Differences in FEV1 and
DLCO Carbon Monoxide Diffusing Capacity
InhaledSC
Adapted from: Skyler J, et al. Diabetes Care. 2007;30:579.
0.3
0.2
0.1
0
-0.1
-0.2
-0.3
-0.4
-0.5
3 6 9 12 15 18 21 24 24
LOCFMonthsChangefromb
aselinein
FEV,
(meanSD
)
Group Differenceat Month 3
=-0.021
Group Difference atMonth 24 LOCF
=-0.023
3
2
1
0
-2
-3
-4
-5
-6
3 6 9 12 15 18 21 24 24
LOCF
Group Differenceat Month 3
=-0.687
Group Difference atMonth 24 LOCF
=-0.439
4
-1
Change
fromb
aselinein
DLB
(mL/min/mmHg)
(m
eanSD)
Baseline
BaselineMonths
Here we see data from a very recently published study by Skyler andcolleagues looking at type 1 diabetes patients and treatment group differencesbetween those treated with Exubera and Comparator subcutaneously injectedinsulin in type 1 individuals looking at both FEV1 and DLCO. Treatment groupdifferences in lung function between Exubera and subcutaneous insulin in
adult patients with type 1 diabetes were small, developed early, and were non-progressive for up to 2 years of therapy similar to what we just saw in the type2 patients.
-
8/9/2019 Incorporating INH for Type2
74/777
Overall Treatment Satisfaction in Patients WithType 2 Diabetes: INH (Exubera) vs SC Insulin
Adapted from: Testa MA, et al. ADA 62nd Annual Meeting. Abstract 544-P. 2002.
Mean Satisfaction Scores at Baseline and Change at Month 6
NOTE: Standardized Treatment Satisfaction Scale ranges from 0 to 100; P
-
8/9/2019 Incorporating INH for Type2
75/777
Availability of Inhaled Insulin and
Acceptance of Insulin Therapy
Adapted from: Freemantle N, et al. Diabetes Care. 2005;28:427-428.
INH available Standard therapy only
00 1010 2020 3030 4040 5050Proportion of Patients (%)
15.515.5
35.335.3
7.97.9
43.343.3
27.427.4
INH
SC Insulin
No ChangeP< 0.0001
Will the availability of inhaled insulin enhance acceptance of insulin therapy amongpatients with type 2 diabetes? This study in which I was an investigator involvedalmost 800 patients in 7 countries with type 2 diabetes. All of the patients wereabove their glycemic goals. Patients were randomized into 2 groups; both groupsreceived information about what the therapeutic glycemic goal was, why it was
important to get to goal, and what are the conventional therapies that could beadded to their regimen. One group also received information about the potentialavailability of inhaled insulin. The patients and their healthcare professionals thenmade a joint theoretical choice of which therapy they would choose including theoption of making no change. Prior to the study, in the opinion of their physicians,about 50% of the patients should have gone on insulin as the next step. Whathappened in response to the study? For patients who only had access to standardtherapy, only about 16% chose to go on insulin. In contrast, nearly 3 times as manypatients chose insulin if inhaled insulin was potentially available and most of thesepatients chose inhaled insulin. Interestingly although none of the patients were atgoal, over 43% of patients who had access to standard therapy only chose to makeno change in their regimen and that number was significantly reduced to 27%among the patients who had the potential availability of inhaled insulin. This wasactually a feasibility trial and the actual study has now been done and in factpatients as opposed to this feasibility trial actually went on the therapy, they choseand were followed for 6 months and these results hopefully will become available inthe not too distant future.
-
8/9/2019 Incorporating INH for Type2
76/777
Improving the Care of People With Type
2 Diabetes
Overweight, obesity, insulin resistance,metabolic syndrome, pre-diabetes, and diabetesare epidemic in our society
Most people with type 2 diabetes do not achievetreatment targets
Most patients will eventually need insulin; butimplementation of insulin is often delayed
Pulmonary inhalation of insulin is effective andappears safe
Inhalation of insulin might facilitate earlierinsulin use and better glycemic control
So, in conclusion overweight, obesity, insulin resistance, pre-diabetes, and diabetesare epidemic in our society. Most people with type 2 diabetes do not achievetreatment targets. Most people will eventually need insulin but implementation ofinsulin is often delayed. Pulmonary inhalation of insulin is effective and appearssafe. Inhalation of insulin might facilitate earlier insulin use and better glycemic
control.
-
8/9/2019 Incorporating INH for Type2
77/77
You have successfully completed the educational portionof our program.
To receive credit for your participation in this educational
activity, please proceed to the Evaluation.
Upon successful completion of the Evaluation you will be
granted immediate access to print your own CE certificate.
Thank you for your participation!
top related